Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2734206 | Imagerie de la Femme | 2016 | 6 Pages |
Abstract
Considering the prognostic difference between stage I, II and stage III, IV of ovarian carcinoma, it was licit to assess the opportunity to perform systematic screening. The available tools are Ca125 and transvaginal ultrasound, which have together a positive predictive value superior to 10% and are thus adapted to such a screening. The recent, randomized studies do not conclude on the efficacy and the cost-effectiveness of ovarian cancer screening for women with standard risk, but also for women presenting an increased risk.
Related Topics
Health Sciences
Medicine and Dentistry
Health Informatics
Authors
Sophie Taïeb, Mariem Ben Haj Amor, Audrey Mailliez, Claude Adenis, Ãric Leblanc,